The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region: Its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients

Pharmacogenetics and Genomics

Volumn 23, Issue 3, 2013, Pages 142-147

  Sebio, Ana ^a   Paré, Laia ^a   Páez, David ^a   Salazar, Juliana ^a,b   González, Alan ^a   Sala, Núria ^a   Del Río, Elisabeth ^a   Martín Richard, Marta ^a   Tobeña, María ^a   Barnadas, Agustí ^a   Baiget, Montserrat ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

anti epidermal growth factor receptor; colorectal cancer; KRAS; let 7 microRNA; polymorphism

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GLUTAMIC ACID; GLYCINE; IRINOTECAN; K RAS PROTEIN; LCS6 PROTEIN; LETHAL 7 PROTEIN; MEMBRANE PROTEIN; MICRORNA; PANITUMUMAB; THREONINE; UNCLASSIFIED DRUG; VALINE;

3' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; BLOOD ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DETERMINATION; DRUG EFFICACY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN TISSUE; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; WILD TYPE;

EID: 84873412791     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835d9b0b     Document Type: Article

References (22)

1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
2. Saltz LB, Meropol NJ, Loehrer PJS, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
3. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-1664.
4. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-1417.
5. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-1634.
6. Wilson PM, Labonte MJ, Lenz HJ. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J 2010; 16:262-272.
7. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753-762.
8. Mishra PJ, Bertino Jr. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009; 10:399-416.
9. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120:635-647.
10. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006; 29:903-906.
11. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3 untranslated region increases non-small cell lung cancer risk. Cancer Res 2008; 68:8535-8540.
12. Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten L, et al. A let-7 microRNA SNP in the KRAS 3UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res 2011; 17:7723-7731.
13. Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, et al. A let-7 microRNA-binding site polymorphism in the KRAS 3 UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009; 30:1003-1007.
14. Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2012; 31:4559-4566.
15. Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, et al. Genetic modulation of the let-7 microRNA binding to KRAS 3-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J 2010; 10: 458-464.
16. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 3-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 2011; 22:104-109.
17. Zhang W, Labonte MJ, Lenz HJ. KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: does treatment combination partner matter? Ann Oncol 2011; 22:484-485.
18. Kohne CH, Cunningham D, Di CF, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13:308-317.
19. Eisenhauer EA, Therasse P, Bogaerts J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
21. Ruzzo A, Canestrari E, Galluccio N, Santini D, Vincenzi B, Tonini G, et al. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients. Ann Oncol 2011; 22:234-235.
22. Ruzzo A, Graziano F, Vicenzi B, Canestrari E, Perrone G, Galluccion N. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 2012; 17:823-829.